An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial

Medical Journal of Australia

Volumn 201, Issue 11, 2014, Pages 671-673

  Laba, Tracey Lea ^a   Hayes, Alison ^b   Lo, Serigne ^a   Peiris, David P ^a   Usherwood, Tim ^c   Hillis, Graham S ^a   Rafter, Natasha ^d,e   Reid, Christopher M ^f   Tonkin, Andrew M ^f   Webster, Ruth ^a   Neal, Bruce C ^a   Cass, Alan ^g   Patel, Anushka ^a   Rodgers, Anthony ^a   Jan, Stephen ^a  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^f MONASH UNIVERSITY   (Australia)

^g MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; FOLLOW UP; HEALTH CARE COST; HUMAN; MEDICARE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DRUG COMBINATION; ECONOMICS; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; AUSTRALIA; CARDIOVASCULAR DISEASES; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; MEDICATION ADHERENCE;

EID: 84924778367     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00266     Document Type: Article

References (18)

1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.
3. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2014; Mar 27 [Epub ahead of print].
4. Thom S, Poulter N, Field J, et al; UMPIRE Collaborative Group. Eff ects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-929.
5. Vos T, Carter R, Barendregt J, et al. Assessing cost-eff ectiveness in prevention (ACEprevention): final report. University of Queensland, Brisbane; Deakin University, Melbourne, 2010.
6. Bautista LE, Vera-Cala LM, Ferrante D, et al. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-eff ective for use in Latin America. Health Aff (Millwood) 2013; 32: 155-164.
7. Ito K, Shrank WH, Avorn J, et al. Comparative cost-eff ectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res 2012; 47: 2097-2117.
8. van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-eff ectiveness in the Dutch population. BMJ Open 2011; 1(2): e000363.
9. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.
10. Australian Bureau of Statistics. Consumer Price Index, Australia, Sep 2013. Table 7. Canberra: ABS, 2013.
11. Doshi J, Glick HA. Economic assessments in randomized trials. Panel discussion, 7th International Conference on Health Policy Statistics; 2008; Philadelphia, PA.
12. Deb P, Manning WG, Norton EC, editors. Modeling health care costs and counts. iHEA World Congress; 2013; Sydney, Australia.
13. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-494.
14. Mihaylova B, Briggs A, O'Hagan A, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ 2011; 20: 897-916.
15. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the pharmaceutical benefits advisory committee (version 4. 4). Canberra: Australian Government Department of Health, 2013.
16. Clarke PM, Avery AB. Evaluating the costs and benefits of using combination therapies. Med J Aust 2014; 200: 518-520.
17. Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Canberra: AIHW, 2011. (AIHW Cat. No. CVD 53; Cardiovascular Disease Series No. 35.).
18. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009; 191: 324-32 9.